Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 5/20 | 0.96 |
| ▸ | DAO | P14920 | 5/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | IDH1 | O75874 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kojic Acid SCHEMBL5011817 | 0.98 | TYR (1.00) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL36895 | 0.98 | TYR (1.00) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28650749 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL30518398 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28808848 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28654757 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL9780977 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28491069 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL6786872 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL29043760 | 0.96 | TYR (0.96) | TYRDAOKDM4EIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103732221-A | Gallium complexes, pharmaceutical compositions and methods of use | GENTA INC | 2014-04-16 | — | — | CN | claimed |
| US-20150175631-A1 | Gallium Complexes, Pharmaceutical Compositions and Methods of Use | ODONATE THERAPEUTICS, LLC | 2015-06-25 | — | — | US | disclosed |
| CN-103732221-A | Gallium complexes, pharmaceutical compositions and methods of use | GENTA INC | 2014-04-16 | — | — | CN | disclosed |
| EP-2688563-A1 | GALLIUM COMPLEXES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | Genta Incorporated (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120245135-A1 | Gallium Complexes, Pharmaceutical Compositions And Methods Of Use | GENTA INCORPORATED (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129473-A1 | GALLIUM COMPLEXES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | GENTA INCORPORATED (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245135-A1 | Gallium Complexes, Pharmaceutical Compositions And Methods Of Use | COG5, CYP3A5, GPR35 | TYR 2265/4885DAO 3818/4885KDM4E 4342/4885 |
| US-20150175631-A1 | Gallium Complexes, Pharmaceutical Compositions and Methods of Use | COG5, CYP3A5, GPR35 | TYR 2265/4885DAO 3818/4885KDM4E 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.